AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASCENTAGE PHARMA GROUP INTERNATIONAL
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 29, 2026
$15.36−0.01 (-0.07%)
Close on Oct 19, 2026
Ascentage Pharma Group International statistics
Financials through Dec 31, 2024, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Market Cap | CN¥9.59B | CN¥1.00B |
| Enterprise Value | CN¥10.41B | CN¥1.59B |
| PS Ratio | 9.78 | |
| PB Ratio | 36.31 | |
| P/TBV Ratio | 40.06 |
Enterprise value
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| EV / Sales | 10.61 |
Income (trailing twelve months)
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Revenue | CN¥980.65M | |
| Gross Profit | CN¥951.57M | |
| Pretax Income | -CN¥395.26M | |
| Net Income | -CN¥405.43M | |
| EPS (Diluted) | -1.34 CNY |
Margins
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Gross Margin | 97.0% | |
| Pretax Margin | -40.3% | |
| Profit Margin | -41.3% | |
| FCF Margin | -13.8% |
Returns
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Return on Equity (ROE) | -249.8% |
Growth
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 341.8% |
Balance sheet
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Cash & Short-Term Investments | CN¥893.10M | |
| Total Debt | CN¥1.70B | |
| Net Cash (Debt) | -CN¥804.74M | |
| Net Cash Per Share | -2.16 CNY | |
| Equity (Book Value) | CN¥264.19M | |
| Book Value Per Share | 0.71 CNY | |
| Tangible Book Value | CN¥239.50M | |
| Working Capital | CN¥307.55M |
Financial position
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Current Ratio | 1.26 | |
| Quick Ratio | 0.84 | |
| Debt / Equity | 6.43 |
Cash flow (trailing twelve months)
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Operating Cash Flow | -CN¥111.36M | |
| Capital Expenditures | -CN¥24.29M | |
| Free Cash Flow | -CN¥135.65M | |
| FCF Per Share | -0.36 CNY |
Efficiency
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Inventory Turnover | 2.56 | |
| Revenue Per Employee | CN¥1.28M | |
| Profits Per Employee | -CN¥528.60K | |
| Employee Count | 767 | 767 |
Dividends and yields
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Earnings Yield | -4.23% | |
| FCF Yield | -1.41% | |
| Buyback Yield | -5.57% | |
| Shareholder Yield | -5.57% |
Shares
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Shares Outstanding | 373,322,000 | 373,322,000 |
| Shares Change (YoY) | 7.00% | 3.69% |
| Float | 324,662,000 | 324,662,000 |
| Shares Held by Insiders | 13.0% | 25.5% |
| Shares Held by Institutions | 0.00% |
Taxes
| Measure | Ascentage Pharma Group International | Industry median |
|---|---|---|
| Income Tax | CN¥10.43M |
Calculated by StockData from Ascentage Pharma Group International's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.